Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3151 to 3200 of 3761 results for treatment

  1. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

  2. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.

  3. Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage (HTG587)

    Evidence-based recommendations on inducing and maintaining normothermia using temperature modulation devices after stroke or subarachnoid haemorrhage in adults. This involves cooling the body using pads placed on the skin or tubes put into the body.

  4. Cardiac contractility modulation device implantation for heart failure (HTG520)

    Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.

  5. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

  6. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  7. Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (HTG654)

    Evidence-based recommendations on laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. This involves placing a ring of beads outside of the food pipe, just above the stomach. Magnets inside the beads hold them together to keep the food pipe closed but are weak enough to move apart to allow food or liquid to be swallowed. The aim is to prevent acid reflux.

  8. Maximal cytoreductive surgery for advanced ovarian cancer (HTG668)

    Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.

  9. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  10. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

  11. Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)

    NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .

  12. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .

  13. Magseed for locating impalpable breast cancer lesions (MIB236)

    NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .

  14. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

  15. Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis (HTG67)

    Evidence-based recommendations on artificial trapeziometacarpal joint replacement for treating end-stage osteoarthritis. This involves replacing the arthritic joint at the base of the thumb with an artificial joint.

  16. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

  17. Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis (HTG617)

    Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction.

  18. The EOS 2D/3D imaging system (HTG274)

    Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.

  19. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    to specialist advice, for example about particular aspects of care and treatment of the person they care for, because this might...

  20. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  21. Blogs

    Preparing for the next breakthroughs in liver disease treatments With no licensed treatments for MASH, a serious liver...

  22. Mini-incision surgery for total knee replacement (HTG220)

    Evidence-based recommendations on mini-incision surgery for total knee replacement. This involves using specially designed instruments to replace the knee using a smaller incision.

  23. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

  24. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

  25. Swallowable gastric balloon capsule for weight loss (HTG561)

    Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that is then filled with liquid to inflate it in the stomach.

  26. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...

  27. Hidden spine fractures could be spotted earlier after NICE recommendation

    NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.

  28. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA855)

    NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.  

  29. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...

  30. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    recommendations on imaging in people who are not going to have radical treatment. There was good evidence that showed that...

  31. Structural neuroimaging in first-episode psychosis (TA136)

    Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.

  32. The NGAL Test for early diagnosis of acute kidney injury (MIB3)

    NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .

  33. CareLink network service for remote monitoring of people with cardiac devices (MIB64)

    NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices

  34. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  35. The PediGuard for placing pedicle screws in spinal surgery (MIB26)

    NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery

  36. What is the clinical and cost effectiveness of chlorhexidine in alcohol at different concentrations in the prevention of surgical site infection when applied to the skin before incision?

    Comes from guidance Surgical site infections: prevention and treatment Number NG125 Date issued April 2019 Other details

  37. Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  38. Our research work

    Our science policy and research programme team produces high-quality, impactful research.

  39. What NICE does

    We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  40. Total wrist replacement (HTG173)

    Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.

  41. Implant insertion for prominent ears (HTG526)

    Evidence-based recommendations on implant insertion for prominent ears in children, young people and adults. This involves inserting small curved implants under the skin of each ear.